Every single time #jazzpharmaceuticals
January 16, 2025 at 12:22 AM
Every single time #jazzpharmaceuticals
Escuchando al profesor Jaime Espín en la II Jornada de Farmacoeconomía #JazzPharmaceuticals @uji.es
February 27, 2025 at 3:16 PM
Escuchando al profesor Jaime Espín en la II Jornada de Farmacoeconomía #JazzPharmaceuticals @uji.es
Gender Pay Gap — Jazz Pharmaceuticals (2025)
Mean hourly gap: +12.0%
Median hourly gap: +21.5%
Mean bonus gap: +21.4%
Median bonus gap: +38.6%
🔗 https://paygap.ie/company/jazzpharmaceuticals
Mean hourly gap: +12.0%
Median hourly gap: +21.5%
Mean bonus gap: +21.4%
Median bonus gap: +38.6%
🔗 https://paygap.ie/company/jazzpharmaceuticals
July 12, 2026 at 1:01 PM
Gender Pay Gap — Jazz Pharmaceuticals (2025)
Mean hourly gap: +12.0%
Median hourly gap: +21.5%
Mean bonus gap: +21.4%
Median bonus gap: +38.6%
🔗 https://paygap.ie/company/jazzpharmaceuticals
Mean hourly gap: +12.0%
Median hourly gap: +21.5%
Mean bonus gap: +21.4%
Median bonus gap: +38.6%
🔗 https://paygap.ie/company/jazzpharmaceuticals
#JazzPharmaceuticals has become the first drugmaker to get #FDA approval for a treatment for diffuse midline #glioma with H3 K27M mutations, a rare #braincancer mainly affecting #youngpeople.
pharmaphorum.com/news/jazz-ge...
pharmaphorum.com/news/jazz-ge...
Jazz gets FDA okay for Chimerix brain cancer drug
Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.
pharmaphorum.com
August 7, 2025 at 10:42 AM
#JazzPharmaceuticals has become the first drugmaker to get #FDA approval for a treatment for diffuse midline #glioma with H3 K27M mutations, a rare #braincancer mainly affecting #youngpeople.
pharmaphorum.com/news/jazz-ge...
pharmaphorum.com/news/jazz-ge...
#JazzPharmaceuticals has been granted #US approval for two combinations of its #cancer drug #Ziihera for people with advanced HER2-positive #gastroesophagealadenocarcinoma.
pharmaphorum.com/news/jazz-se...
pharmaphorum.com/news/jazz-se...
Jazz secures FDA approval for Ziihera in first-line HER2-positive GEA
Jazz Pharmaceuticals has been granted US approval for two combinations of its cancer drug Ziihera HER2+ advanced GEA.
pharmaphorum.com
August 26, 2026 at 2:04 PM
#JazzPharmaceuticals has been granted #US approval for two combinations of its #cancer drug #Ziihera for people with advanced HER2-positive #gastroesophagealadenocarcinoma.
pharmaphorum.com/news/jazz-se...
pharmaphorum.com/news/jazz-se...
#CNXTherapeutics #Sativex #nabiximols #JazzPharmaceuticals #plantderivedcannabinoidmedicine #cannabinoidmedicine #CNS #CNSportfolio #patientaccess #multiplesclerosis #MS #MSpatients #marketingauthorisations #commercialpartnerships #manufacturingarrangements #CNSmedicines
zurl.co/X5Tvc
zurl.co/X5Tvc
CNX Therapeutics acquires Sativex from Jazz Pharmaceuticals - PharmaTimes
Deal strengthens CNS portfolio and ensures continuity of access for MS patients
pharmatimes.com
November 4, 2025 at 1:00 PM
#gastrointestinalcancers #EC #JazzPharmaceuticals #Ziihera #zanidatamab #advancedbiliarytractcancer #biliarytractcancer #BTCpatients #HER2targetedbispecificantibody #HERIZONBTC01trial #gallbladdercancer #cholangiocarcinoma #advancedHER2positiveBTC #HER2targetedtherapy
pmlive.com/pharma_news/...
pmlive.com/pharma_news/...
EC approves Jazz Pharmaceuticals’ Ziihera for advanced biliary tract cancer - PMLiVE
Approximately 26% of biliary tract cancer patients globally have HER2-positive disease
pmlive.com
July 10, 2025 at 8:15 AM